The winding journey of biotech capital raising: deciphering the jargon.

Autor: Frame N; Outcome Capital, LLC, 99 High Street Suite 2900, Boston, MA 02110, USA. Electronic address: nframe@outcomecapital.com., Casasanta M; Outcome Capital, LLC, 99 High Street Suite 2900, Boston, MA 02110, USA., Ben-Joseph O; Outcome Capital, LLC, 99 High Street Suite 2900, Boston, MA 02110, USA.
Jazyk: angličtina
Zdroj: Trends in biotechnology [Trends Biotechnol] 2023 Oct; Vol. 41 (10), pp. 1213-1215. Date of Electronic Publication: 2023 Jul 12.
DOI: 10.1016/j.tibtech.2023.06.011
Abstrakt: Ensuring biotech companies are sufficiently capitalized to propel innovation and development remains a central focus for management. In this article, we draw on our broad perspective interacting with venture capitalists to offer thoughts on investor feedback. Understanding venture capitalists' mindsets and investment theses will increase the probability of securing needed capital.
Competing Interests: Declaration of interests N.F., M.C., and O.B.J. are members of the investment banking team at Outcome Capital, a life sciences and healthcare specialized advisory and investment banking firm in Boston, MA, USA assisting companies in capital raising and merger and acquisition transactions. O.B.J. serves as a member of the board of directors for Elios Vision.
(Copyright © 2023 Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: